Cell Genesys to Webcast Presentation At The Rodman & Renshaw Techvest Healthcare Conference
Thursday October 16, 9:00 am ET
SOUTH SAN FRANCISCO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE - News), today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys, will present a company update at the Rodman & Renshaw Techvest Healthcare Conference in Boston, MA that will be broadcast live over the internet on Tuesday, October 21, 2003, at 11:40 a.m. EDT.
The webcast will be available on the Investor Relations section of the Cell Genesys website, www.cellgenesys.com. If you are unable to listen to the live webcast, it will be archived on the site for at least 48 hours following the presentation. To access the replay, go to the Investor Relations section of the site.
Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is pursuing three cancer product platforms -- GVAX® cancer vaccines, oncolytic virus therapies and cancer gene therapies. Clinical trials of GVAX® vaccines are under way in prostate cancer, lung cancer, pancreatic cancer, leukemia and myeloma. Clinical programs of oncolytic virus therapies include CG7870 for prostate cancer. Preclinical studies are in progress for additional GVAX® cancer vaccines, oncolytic virus therapies and cancer gene therapies for multiple types of cancer. Cell Genesys' majority-owned subsidiary, Ceregene, Inc., is focused on gene therapies for neurologic disorders. Cell Genesys also continues to hold an equity interest in its former subsidiary, Abgenix, Inc., an antibody products company. Cell Genesys is headquartered in South San Francisco, CA and has manufacturing operations in San Diego, CA, Hayward, CA and Memphis, TN. For additional information, please visit the company's website at www.cellgenesys.com.
Statements made herein about Cell Genesys and its subsidiaries, other than statements of historical fact, including statements about the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of research and development programs, the success of clinical trials, the regulatory approval process, competitive technologies and products, patents and additional financings. For information about these and other risks which may affect Cell Genesys, please see the company's Annual Report on Form 10-K dated March 31, 2003 as well as Cell Genesys' reports on Forms 10-Q and 8-K and other reports filed with the Securities and Exchange Commission.
CONTACT: Jennifer Cook Williams, Director, Corporate Communications and Investor Relations, +1-650-266-3200.
Source: Cell Genesys, Inc. |
